Skip to content
Screener

Ardelyx ARDX Net Change in Cash

Net Change in Cash at other companies

Amgen logo
AmgenAMGN
$1.95B+349%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$13M+70.5%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
-$141.34M
AbbVie logo
AbbVieABBV
$4.16B+1,293%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$6.28M-353%
XER
Xeris Biopharma Holdings, Inc.XERS
$10M+1,083%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Repayment of Loan Agreement, including fees(33,831)
Proceeds from issuance of common stock under equity incentive plans7,1222,470
Net cash provided by financing activities55,16251,138
Net increase in cash and cash equivalents29,19225,113
Cash and cash equivalents at beginning of period67,99964,932
Cash and cash equivalents at end of period$97,191$90,045
Supplemental disclosure of cash flow information
Cash paid for interest$7,745$6,280

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's net change in cash?
Ardelyx (ARDX) reported net change in cash of $65.98M in Q2 2026.
How has Ardelyx's net change in cash changed year-over-year?
Ardelyx's net change in cash increased by 11.4% year-over-year, from $59.24M to $65.98M.
What is the long-term trend for Ardelyx's net change in cash?
Over 2 years (2023 to 2025), Ardelyx's net change in cash has grown at a -80.2% compound annual growth rate (CAGR), from -$78.38M to $3.07M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Ardelyx's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude